European Pharmaceutical Review

OCTOBER 19, 2022

Patents are often described as the ‘lifeblood’ of pharmaceutical companies. 1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment.

FDA 96

FDA Dosage Pharmaceutical Companies Pharmaceutical Companies 96

The Checkup by Singlecare

AUGUST 14, 2024

Although GLP-1 drugs have been around since 2005, Ozempic was only made available in 2017. When a drug is in the pipeline of a clinical trial, the FDA requires the pharmaceutical company to be very specific in their hypothesis and tested patient population,” she explains. Ozempic was only tested on patients with Type 2 diabetes.

Labelling 52

Labelling FDA Insurance Insurance Coverage 52

The Checkup by Singlecare

OCTOBER 3, 2024

Food and Drug Administration (FDA) approval in 2005 to treat Type 2 Diabetes Mellitus (T2DM). Compare Zepbound alternatives Drug name Uses Dosage Savings options Zepbound (tirzepatide) Weight management, chronic 2.5 Since that time, multiple GLP-1 agonists have received FDA approval for the management of T2DM.

FDA 52

FDA Insurance Coverage Insurance Dosage 52

ISPE

MAY 9, 2023

In an era when the world is accelerating the development of drugs and targeted medicines using innovative technologies, pharmaceutical companies still face registration hurdles for well-characterized molecules because of redundant or additional local regulatory requirements. Published 19 January 2005. Published November 2005.

Documentation 52

Documentation Packaging Pharmaceutical Companies Pharmaceutical Companies 52